Tags

Type your tag names separated by a space and hit enter

Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine.
Hum Psychopharmacol 2010; 25(2):145-52HP

Abstract

OBJECTIVE

To explore the association of brain-derived neurotrophic-factor (BDNF) Val66Met polymorphism with both baseline health related quality of life (HRQOL) scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine.

METHODS

Patients with major depressive disorder (MDD) took fluoxetine (20 mg/day) for 6 weeks. The HRQOL was measured with the Medical Outcomes Study Short Form-36 (SF-36) at baseline and at 6th week. Patients were genotyped for Val66Met polymorphism of BDNF gene.

RESULTS

There was a significant association between social function (SF) and BDNF Val66Met polymorphism, and patients with Met/Met genotype had better SF (compared with Val/Val P = 0.004; compared with Val/Met P = 0.005). A significant association was found between improvement in SF and BDNF Val66Met polymorphism, and patients with Met/Met genotype had poorer improvement in SF (compared with Val/Val P = 0.010; compared with Val/Met P = 0.001). Similar association was found between improvement in mental component summary (MCS) and BDNF Val66Met polymorphism, and patients with Met/Met genotype had poorer improvement in MCS (compared with Val/Val P = 0.066; compared with Val/Met P = 0.006).

CONCLUSIONS

These results indicate that there may be association between BDNF Val66Met polymorphism and both baseline HRQOL (SF) scores and improvement in HRQOL (SF, MCS) scores in Chinese major depressive patients treated with fluoxetine.

Authors+Show Affiliations

Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study

Language

eng

PubMed ID

20196181

Citation

Zou, Yan-Feng, et al. "Association of BDNF Val66Met Polymorphism With Both Baseline HRQOL Scores and Improvement in HRQOL Scores in Chinese Major Depressive Patients Treated With Fluoxetine." Human Psychopharmacology, vol. 25, no. 2, 2010, pp. 145-52.
Zou YF, Wang Y, Liu P, et al. Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine. Hum Psychopharmacol. 2010;25(2):145-52.
Zou, Y. F., Wang, Y., Liu, P., Feng, X. L., Wang, B. Y., Zang, T. H., ... Xu, X. P. (2010). Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine. Human Psychopharmacology, 25(2), pp. 145-52. doi:10.1002/hup.1099.
Zou YF, et al. Association of BDNF Val66Met Polymorphism With Both Baseline HRQOL Scores and Improvement in HRQOL Scores in Chinese Major Depressive Patients Treated With Fluoxetine. Hum Psychopharmacol. 2010;25(2):145-52. PubMed PMID: 20196181.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Association of BDNF Val66Met polymorphism with both baseline HRQOL scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine. AU - Zou,Yan-Feng, AU - Wang,Yu, AU - Liu,Ping, AU - Feng,Xiao-Liang, AU - Wang,Bin-Yan, AU - Zang,Tong-Hua, AU - Yu,Xin, AU - Wei,Jing, AU - Liu,Zhong-Chun, AU - Liu,Ying, AU - Tao,Ming, AU - Li,Hui-Chun, AU - Li,Ke-Qing, AU - Hu,Jian, AU - Li,Ming, AU - Zhang,Ke-Rang, AU - Ye,Dong-Qing, AU - Xu,Xi-Ping, PY - 2010/3/3/entrez PY - 2010/3/3/pubmed PY - 2010/6/15/medline SP - 145 EP - 52 JF - Human psychopharmacology JO - Hum Psychopharmacol VL - 25 IS - 2 N2 - OBJECTIVE: To explore the association of brain-derived neurotrophic-factor (BDNF) Val66Met polymorphism with both baseline health related quality of life (HRQOL) scores and improvement in HRQOL scores in Chinese major depressive patients treated with fluoxetine. METHODS: Patients with major depressive disorder (MDD) took fluoxetine (20 mg/day) for 6 weeks. The HRQOL was measured with the Medical Outcomes Study Short Form-36 (SF-36) at baseline and at 6th week. Patients were genotyped for Val66Met polymorphism of BDNF gene. RESULTS: There was a significant association between social function (SF) and BDNF Val66Met polymorphism, and patients with Met/Met genotype had better SF (compared with Val/Val P = 0.004; compared with Val/Met P = 0.005). A significant association was found between improvement in SF and BDNF Val66Met polymorphism, and patients with Met/Met genotype had poorer improvement in SF (compared with Val/Val P = 0.010; compared with Val/Met P = 0.001). Similar association was found between improvement in mental component summary (MCS) and BDNF Val66Met polymorphism, and patients with Met/Met genotype had poorer improvement in MCS (compared with Val/Val P = 0.066; compared with Val/Met P = 0.006). CONCLUSIONS: These results indicate that there may be association between BDNF Val66Met polymorphism and both baseline HRQOL (SF) scores and improvement in HRQOL (SF, MCS) scores in Chinese major depressive patients treated with fluoxetine. SN - 1099-1077 UR - https://www.unboundmedicine.com/medline/citation/20196181/Association_of_BDNF_Val66Met_polymorphism_with_both_baseline_HRQOL_scores_and_improvement_in_HRQOL_scores_in_Chinese_major_depressive_patients_treated_with_fluoxetine_ L2 - https://doi.org/10.1002/hup.1099 DB - PRIME DP - Unbound Medicine ER -